Multinational Validation of PREVENT and SCORE2 Cardiovascular Risk Equations
A comprehensive study published in Nature Medicine validates the performance of two major cardiovascular risk prediction tools: the American Heart Association’s PREVENT equations and Europe’s SCORE2 algorithm. Analyzing data from 44 observational cohorts and 18 randomized trials involving over 6.4 million individuals, researchers assessed the discrimination and calibration of these models across diverse geographical regions, including North America, Europe, and Asia. The study observed hundreds of thousands of cardiovascular events over a mean follow-up period of 5.1 years. Results indicated that despite differences in outcome definitions and target populations, both equations demonstrated similar and generally good performance globally. Additionally, the research team developed scaling factors for the PREVENT equations to enable shorter-term risk prediction, facilitating clinical trial enrollment and research. These findings support the broader adoption of either PREVENT or SCORE2 for cardiovascular risk stratification in varied clinical settings, providing robust evidence for their utility in guiding lipid and blood pressure-lowering therapies worldwide.
Wire timeline
Multinational Validation of PREVENT and SCORE2 Cardiovascular Risk Equations
A comprehensive study published in Nature Medicine validates the performance of two major cardiovascular risk prediction tools: the American Heart Association’s PREVENT equations and Europe’s SCORE2 algorithm. Analyzing data from 44 observational cohorts and 18 randomized trials involving over 6.4 million individuals, researchers assessed the discrimination and calibration of these models across diverse geographical regions, including North America, Europe, and Asia. The study observed hundreds of thousands of cardiovascular events over a mean follow-up period of 5.1 years. Results indicated that despite differences in outcome definitions and target populations, both equations demonstrated similar and generally good performance globally. Additionally, the research team developed scaling factors for the PREVENT equations to enable shorter-term risk prediction, facilitating clinical trial enrollment and research. These findings support the broader adoption of either PREVENT or SCORE2 for cardiovascular risk stratification in varied clinical settings, providing robust evidence for their utility in guiding lipid and blood pressure-lowering therapies worldwide.
Nature Medicine